Clinical trials: Skin Diseases, Papulosquamous
Scarring Alopecia, Frontal Fibrosing Alopecia
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.
- Conditions
- Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia
- Trial name
- NCT03346668
- Testing
- Topical gabapentin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Minnesota
Psoriatic Arthritis
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
This is a study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis.
- Trial name
- BE ACTIVE (NCT02969525)
- Testing
- Bimekizumab
- Where
- 40 sites in United States, Czechia and 4 more
- Volunteers
- 206 people
- Sponsor
- UCB Biopharma S.P.R.L.
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Psoriasis
Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions
The purpose of this study is to understand the role of a specific protein, tumor protein p63 in the skin disease psoriasis. This study is to further understand how psoriasis lesions happens.
- Trial name
- NCT04560647
- Testing
- No intervention - Psoriasis Subject, No intervention - Control Subject
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Wright State University
Psoriasis, Psoriatic Arthritis
SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE
This is a single-label open-arm mechanistic clinical study recruiting patients with psoriasis or psoriatic arthritis with elevated cardiovascular risk.
- Conditions
- Psoriasis, Psoriatic Arthritis, Cardiovascular Risk Factor
- Trial name
- INSPIRE (NCT04417114)
- Testing
- Rosuvastatin
- Sponsor
- Brigham and Women's Hospital
Psoriasis, Vascular Inflammation
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.
- Conditions
- Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
- Trial name
- NCT01722214
- Testing
- Adalimumab
- Where
- 5 sites in Canada
- Volunteers
- 107 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis, Stress
12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN
This is a 12-Week, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate to severe psoriasis treated with TEN.
- Trial name
- NCT03511755
- Testing
- Transdermal Electrical Neuromodulator (TEN)
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Thync Global, Inc.
Psoriasis, Plaque Psoriasis
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of…
- Trial name
- NCT01700985
- Testing
- 122-0551, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Therapeutics, Inc.
Psoriasis
Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
- Trial name
- NCT03873415
- Testing
- BMS-986165
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis, Administration, Topical
Microneedle Patch for Psoriatic Plaques
The purpose of this study is to evaluate the efficacy of microneedle patch on the psoriatic plaques.
- Trial name
- NCT02955576
- Testing
- Microneedle HA patch, Patch, Control
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- The Catholic University of Korea
Psoriatic Arthritis
FAPI-PET/CT in Psoriatic Arthritis
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease.
- Trial name
- NCT05686876
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Atopic Dermatitis, Contact Dermatitis
Exploratory Study of Natural Killer Cells in Human Skin
Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time…
- Conditions
- Atopic Dermatitis, Contact Dermatitis, Psoriasis, Lichen Planus
- Trial name
- NCT00824889
- Testing
- Biopsy and sample of blood
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Psoriasis
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety, pharmacokinetics, and efficacy.
- Trial name
- NCT00443326
- Testing
- AMG 714
- Volunteers
- 22 people
- Sponsor
- Amgen
Psoriasis
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis.
- Trial name
- NCT07471048
- Testing
- Oral supplement containing 200mg Magnolia officinalis bark extract
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sirt3 LLC
Oral Lichen Planus
Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus
The study included forty individuals divided into 3 groups. 10 control subjects, 15 oral lichen planus (OLP) patients who were treated with topical corticosteroids and 15 oral lichen planus (OLP) patients who were treated with…
- Trial name
- NCT02329600
- Testing
- green tea tablets (Green tea extract 5:1) 200 mg, Triamcinolone Acetonide
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cairo University
Psoriasis (PsO)
A Study to Assess Deucravacitinib Safety in Pregnancy
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were…
- Trial name
- NCT07017699
- Testing
- Deucravacitinib, Other systemic treatments for PsO
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Transitioning From Cyclosporine to Alefacept in Psoriasis
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.
- Trial name
- NCT00143806
- Testing
- Transitioning patients from cyclosporine to alefacept
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with…
- Trial name
- BE ABLE 1 (NCT02905006)
- Testing
- Bimekizumab
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 250 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriasis
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis. There will be 2 study cohorts (Cohorts A and B).
- Trial name
- NCT01782664
- Testing
- 100 mg GSK2586184, 200 mg GSK2586184, 400 mg GSK2586184
- Where
- 15 sites in Germany, United Kingdom
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Psoriasis, Cardiovascular Disease
Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study
There is growing evidence that psoriasis is a systemic disorder which enhances atherosclerosis and the risk of cardiovascular disease.
- Trial name
- NCT01382784
- Where
- 2 sites in Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.